Breast Cancer Clinical Trials in Philadelphia

Showing 621-640 of 783 trials

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

NCT01091428

This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).

Ovarian CarcinomaFallopian Tube CancerPeritoneal Cancer+1 more

Millennium Pharmaceuticals, Inc.191 participantsStarted Apr 2010

The Bronx, New York, United States • Philadelphia, Pennsylvania, United States • Houston, Texas, United States +1 more locations

COMPLETEDPhase 1< 1 mile

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437

RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn more about the effects of ritonavir on biomarkers involved in breast cancer growth. PURPOSE: This phase I/II trial is studying the best dose of ritonavir and its effects on biomarkers in women undergoing surgery for newly diagnosed breast cancer.

Breast Cancer

Masonic Cancer Center, University of Minnesota28 participantsStarted May 2010

Minneapolis, Minnesota, United States • Philadelphia, Pennsylvania, United States

WITHDRAWN< 1 mile

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

NCT00899145

This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers. Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors identify biomarkers related to cancer.

BRCA1 Mutation CarrierBRCA2 Mutation CarrierBreast Carcinoma

Gynecologic Oncology GroupStarted May 2008

Philadelphia, Pennsylvania, United States

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Cancer Trials in Other Cities

Digital Mammography Screening Trial (ACRIN6652)

Cryoablation of Small Breast Tumors in Early Stage Breast Cancer

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

NOLAN: Naproxen or Loratadine and Neulasta

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

Mastectomy Reconstruction Outcomes Consortium (MROC) Study

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Other Conditions in Philadelphia